Given that IFN-γ is crucial to the anti-tumor immunity in microenvironment, the association between FGFR3 and PD-L1 levels in the presence of IFN-γ is largely underexplored in BC, prompting us to evaluate the effect of FGFR inhibitors on IFN-γ-induced PD-L1 and its molecular mechanisms in FGFR3-activated NMIBC cells. The gene discussed is IFNG; the disease is breast cancer.